Skip to main content
Top
Published in: BMC Neurology 1/2024

Open Access 01-12-2024 | Spinal Muscular Atrophy | Research

Optimized MLPA workflow for spinal muscular atrophy diagnosis: identification of a novel variant, NC_000005.10:g.(70919941_70927324)del in isolated exon 1 of SMN1 gene through long-range PCR

Authors: Mei Yao, Liya Jiang, Yicheng Yu, Yiqin Cui, Yuwei Chen, Dongming Zhou, Feng Gao, Shanshan Mao

Published in: BMC Neurology | Issue 1/2024

Login to get access

Abstract

Background

Spinal muscular atrophy (SMA) is a rare autosomal recessive hereditary neuromuscular disease caused by survival motor neuron 1 (SMN1) gene deletion or mutation. Homozygous deletions of exon 7 in SMN1 result in 95% of SMA cases, while the remaining 5% are caused by other pathogenic variants of SMN1.

Methods

We analyzed two SMA-suspected cases that were collected, with no SMN1 gene deletion and point mutation in whole-exome sequencing. Exon 1 deletion of the SMN gene was detected using Multiplex ligation-dependent probe amplification (MLPA) P021. We used long-range polymerase chain reaction (PCR) to isolate the SMN1 template, optimized-MLPA P021 for copy number variation (CNV) analysis within SMN1 only, and validated the findings via third-generation sequencing.

Results

Two unrelated families shared a genotype with one copy of exon 7 and a novel variant, g.70919941_70927324del, in isolated exon 1 of the SMN1 gene. Case F1-II.1 demonstrated no exon 1 but retained other exons, whereas F2-II.1 had an exon 1 deletion in a single SMN1 gene. The read coverage in the third-generation sequencing results of both F1-II.1 and F2-II.1 revealed a deletion of approximately 7.3 kb in the 5’ region of SMN1. The first nucleotide in the sequence data aligned to the 7385 bp of NG_008691.1.

Conclusion

Remarkably, two proband families demonstrated identical SMN1 exon 1 breakpoint sites, hinting at a potential novel mutation hotspot in Chinese SMA, expanding the variation spectrum of the SMN1 gene and corroborating the specificity of isolated exon 1 deletion in SMA pathogenesis. The optimized-MLPA P021 determined a novel variant (g.70919941_70927324del) in isolated exon 1 of the SMN1 gene based on long-range PCR, enabling efficient and affordable detection of SMN gene variations in patients with SMA, providing new insight into SMA diagnosis to SMN1 deficiency and an optimized workflow for single exon CNV testing of the SMN gene.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med. 2013;19:40–50.CrossRefPubMed Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med. 2013;19:40–50.CrossRefPubMed
2.
go back to reference Shababi M, Lorson CL, Rudnik-Schöneborn SS. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? J Anat. 2014;224:15–28.CrossRefPubMed Shababi M, Lorson CL, Rudnik-Schöneborn SS. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? J Anat. 2014;224:15–28.CrossRefPubMed
3.
go back to reference Yao M, Ma Y, Qian R, Xia Y, Yuan C, Bai G, et al. Quality of life of children with spinal muscular atrophy and their caregivers from the perspective of caregivers: a Chinese cross-sectional study. Orphanet J Rare Dis. 2021;16:7.CrossRefPubMedPubMedCentral Yao M, Ma Y, Qian R, Xia Y, Yuan C, Bai G, et al. Quality of life of children with spinal muscular atrophy and their caregivers from the perspective of caregivers: a Chinese cross-sectional study. Orphanet J Rare Dis. 2021;16:7.CrossRefPubMedPubMedCentral
4.
go back to reference Russman BS. Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol. 2007;22:946–51.CrossRefPubMed Russman BS. Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol. 2007;22:946–51.CrossRefPubMed
5.
go back to reference Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11:443–52.CrossRefPubMed Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11:443–52.CrossRefPubMed
6.
go back to reference Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy - New phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7:1–13.CrossRefPubMedPubMedCentral Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy - New phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7:1–13.CrossRefPubMedPubMedCentral
8.
go back to reference Mercuri E, Pera MC, Scoto M, Finkel R, Muntoni F. Spinal muscular atrophy - insights and challenges in the treatment era. Nat Rev Neurol. 2020;16:706–15.CrossRefPubMed Mercuri E, Pera MC, Scoto M, Finkel R, Muntoni F. Spinal muscular atrophy - insights and challenges in the treatment era. Nat Rev Neurol. 2020;16:706–15.CrossRefPubMed
9.
go back to reference Ahmad S, Bhatia K, Kannan A, Gangwani L. Molecular mechanisms of neurodegeneration in spinal muscular atrophy. J Exp Neurosci. 2016;23:39–49. Ahmad S, Bhatia K, Kannan A, Gangwani L. Molecular mechanisms of neurodegeneration in spinal muscular atrophy. J Exp Neurosci. 2016;23:39–49.
10.
go back to reference Keinath MC, Prior DE, Prior TW. Spinal muscular atrophy: mutations, testing, and clinical relevance. Appl Clin Genet. 2021;25:11–25.CrossRef Keinath MC, Prior DE, Prior TW. Spinal muscular atrophy: mutations, testing, and clinical relevance. Appl Clin Genet. 2021;25:11–25.CrossRef
11.
go back to reference Faravelli I, Nizzardo M, Comi GP, Corti S. Spinal muscular atrophy–recent therapeutic advances for an old challenge. Nat Rev Neurol. 2015;11:351–9.CrossRefPubMed Faravelli I, Nizzardo M, Comi GP, Corti S. Spinal muscular atrophy–recent therapeutic advances for an old challenge. Nat Rev Neurol. 2015;11:351–9.CrossRefPubMed
12.
go back to reference Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, Gillingwater TH, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81:355–68.CrossRefPubMedPubMedCentral Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, Gillingwater TH, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81:355–68.CrossRefPubMedPubMedCentral
13.
go back to reference Groen EJN, Talbot K, Gillingwater TH. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol. 2018;14:214–24.CrossRefPubMed Groen EJN, Talbot K, Gillingwater TH. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol. 2018;14:214–24.CrossRefPubMed
14.
go back to reference Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723–32.CrossRefPubMed Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723–32.CrossRefPubMed
15.
go back to reference Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625–35.CrossRefPubMed Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625–35.CrossRefPubMed
16.
go back to reference Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study. Lancet Child Adolesc Health. 2021;5:491–500.CrossRefPubMed Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study. Lancet Child Adolesc Health. 2021;5:491–500.CrossRefPubMed
17.
go back to reference De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29:842–56.CrossRefPubMedPubMedCentral De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29:842–56.CrossRefPubMedPubMedCentral
18.
go back to reference Darras BT, Masson R, Mazurkiewicz-Bełdzińska M, Rose K, Xiong H, Zanoteli E, et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385:427–35.CrossRefPubMed Darras BT, Masson R, Mazurkiewicz-Bełdzińska M, Rose K, Xiong H, Zanoteli E, et al. Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med. 2021;385:427–35.CrossRefPubMed
19.
go back to reference Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384:915–23.CrossRefPubMed Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384:915–23.CrossRefPubMed
20.
go back to reference Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:832–41.CrossRefPubMed Mercuri E, Muntoni F, Baranello G, Masson R, Boespflug-Tanguy O, Bruno C, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:832–41.CrossRefPubMed
21.
go back to reference Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103–15.CrossRefPubMed Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103–15.CrossRefPubMed
22.
go back to reference Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28:197–207.CrossRefPubMed Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28:197–207.CrossRefPubMed
23.
go back to reference Anthony R, Kin FA. PacBio sequencing and its applications. Gen Proteomics Bioinform. 2015;13:278–89.CrossRef Anthony R, Kin FA. PacBio sequencing and its applications. Gen Proteomics Bioinform. 2015;13:278–89.CrossRef
24.
go back to reference Kubo Y, Nishio H, Saito K. A new method for SMN1 and hybrid SMN gene analysis in spinal muscular atrophy using long-range PCR followed by sequencing. J Hum Genet. 2015;60:233–9.CrossRefPubMed Kubo Y, Nishio H, Saito K. A new method for SMN1 and hybrid SMN gene analysis in spinal muscular atrophy using long-range PCR followed by sequencing. J Hum Genet. 2015;60:233–9.CrossRefPubMed
25.
go back to reference Zhao X, Wang Y, Mei S, Chen C, Liu L, Wang C, et al. Identification of two novel SMN1 point mutations associated with a very severe SMA-I phenotype. Eur J Med Genet. 2020;63:104006.CrossRefPubMed Zhao X, Wang Y, Mei S, Chen C, Liu L, Wang C, et al. Identification of two novel SMN1 point mutations associated with a very severe SMA-I phenotype. Eur J Med Genet. 2020;63:104006.CrossRefPubMed
26.
go back to reference van Dijk EL, Jaszczyszyn Y, Naquin D, Thermes C. The third revolution in sequencing technology. Trends Genet. 2018;34:666–81.CrossRefPubMed van Dijk EL, Jaszczyszyn Y, Naquin D, Thermes C. The third revolution in sequencing technology. Trends Genet. 2018;34:666–81.CrossRefPubMed
27.
go back to reference Li S, Han X, Xu Y, Chang C, Gao L, Li J, et al. Comprehensive analysis of spinal muscular atrophy: SMN1 copy number, intragenic mutation, and 2 + 0 carrier analysis by third-generation sequencing. J Mol Diagn. 2022;24:1009–20.CrossRefPubMed Li S, Han X, Xu Y, Chang C, Gao L, Li J, et al. Comprehensive analysis of spinal muscular atrophy: SMN1 copy number, intragenic mutation, and 2 + 0 carrier analysis by third-generation sequencing. J Mol Diagn. 2022;24:1009–20.CrossRefPubMed
28.
go back to reference Arkblad EL, Darin N, Berg K, Kimber E, Brandberg G, Lindberg C, et al. Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy. Neuromuscul Disord. 2006;16:830–8.CrossRefPubMed Arkblad EL, Darin N, Berg K, Kimber E, Brandberg G, Lindberg C, et al. Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy. Neuromuscul Disord. 2006;16:830–8.CrossRefPubMed
29.
go back to reference Clermont O, Burlet P, Benit P, Chanterau D, Saugier-Veber P, Munnich A, et al. Molecular analysis of SMA patients without homozygous SMN1 deletions using a new strategy for identification of SMN1 subtle mutations. Hum Mutat. 2004;24:417–27.CrossRefPubMed Clermont O, Burlet P, Benit P, Chanterau D, Saugier-Veber P, Munnich A, et al. Molecular analysis of SMA patients without homozygous SMN1 deletions using a new strategy for identification of SMN1 subtle mutations. Hum Mutat. 2004;24:417–27.CrossRefPubMed
30.
go back to reference Zhang W, Cao Y, Song F, Qu Y, Bai J, Jin Y, et al. Analysis of SMN1 gene partial deletion of spinal muscular atrophy based on MLPA. Zhonghua Yi Xue Za Zhi. 2015;95:430–4.PubMed Zhang W, Cao Y, Song F, Qu Y, Bai J, Jin Y, et al. Analysis of SMN1 gene partial deletion of spinal muscular atrophy based on MLPA. Zhonghua Yi Xue Za Zhi. 2015;95:430–4.PubMed
31.
go back to reference Bai J, Qu Y, OuYang S, Jiao H, Wang Y, Li J, et al. Novel Alu-mediated deletions of the SMN1 gene were identified by ultra-long read sequencing technology in patients with spinal muscular atrophy. Neuromuscul Disord. 2023;33:382–90.CrossRefPubMed Bai J, Qu Y, OuYang S, Jiao H, Wang Y, Li J, et al. Novel Alu-mediated deletions of the SMN1 gene were identified by ultra-long read sequencing technology in patients with spinal muscular atrophy. Neuromuscul Disord. 2023;33:382–90.CrossRefPubMed
32.
go back to reference Wijaya YOS, Ar Rohmah M, Niba ETE, Morisada N, Noguchi Y, Hidaka Y, et al. Phenotypes of SMA patients retaining SMN1 with intragenic mutation. Brain Dev. 2021;43:745–58.CrossRefPubMed Wijaya YOS, Ar Rohmah M, Niba ETE, Morisada N, Noguchi Y, Hidaka Y, et al. Phenotypes of SMA patients retaining SMN1 with intragenic mutation. Brain Dev. 2021;43:745–58.CrossRefPubMed
Metadata
Title
Optimized MLPA workflow for spinal muscular atrophy diagnosis: identification of a novel variant, NC_000005.10:g.(70919941_70927324)del in isolated exon 1 of SMN1 gene through long-range PCR
Authors
Mei Yao
Liya Jiang
Yicheng Yu
Yiqin Cui
Yuwei Chen
Dongming Zhou
Feng Gao
Shanshan Mao
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2024
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-024-03592-5

Other articles of this Issue 1/2024

BMC Neurology 1/2024 Go to the issue